ANIK Anika Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIK

Price (delayed)

$21.17

Market cap

$283.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.26

Enterprise value

$268.22M

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 46

Anika Therapeutics, Inc., is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most ...

Highlights
The net income has surged by 94% year-on-year and by 66% since the previous quarter
The company's EPS has surged by 94% YoY and by 67% QoQ
ANIK's equity is down by 7% year-on-year but it is up by 2.5% since the previous quarter
Anika Therapeutics's quick ratio has decreased by 36% YoY and by 4.4% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.anikatherapeutics.com
Peers: MDT SYK STAA JNJ

Key stats

What are the main financial stats of ANIK

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-3.9%
1 week
5.01%
1 month
34.24%
1 year
133.15%
YTD
120.29%
QTD
44.7%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$120.65M
Gross profit
$75M
Operating income
-$5.12M
Net income
-$3.78M
Gross margin
62.2%
Net margin
-3.1%
Anika Therapeutics's net margin has surged by 94% YoY and by 67% QoQ
The net income has surged by 94% year-on-year and by 66% since the previous quarter
Anika Therapeutics's operating margin has soared by 60% from the previous quarter and by 48% YoY
Anika Therapeutics's operating income has soared by 58% from the previous quarter and by 45% YoY

Price vs fundamentals

How does ANIK's price correlate with its fundamentals

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
ANIK P/E details
P/E
N/A
P/B
2.05
P/S
2.34
EV/EBIT
N/A
EV/EBITDA
67.39
EV/Sales
2.22
The company's EPS has surged by 94% YoY and by 67% QoQ
ANIK's price to book (P/B) is 71% more than its last 4 quarters average of 1.2 and 46% more than its 5-year quarterly average of 1.4
ANIK's equity is down by 7% year-on-year but it is up by 2.5% since the previous quarter
ANIK's P/S is 67% above its last 4 quarters average of 1.4 but 10% below its 5-year quarterly average of 2.6
The revenue has grown by 5% YoY and by 3.8% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance
The company's return on sales has surged by 94% YoY and by 66% QoQ
The ROIC has soared by 93% year-on-year and by 65% since the previous quarter
Anika Therapeutics's ROE has soared by 93% YoY and by 65% from the previous quarter
The return on assets has surged by 93% year-on-year and by 66% since the previous quarter

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's quick ratio has decreased by 36% YoY and by 4.4% from the previous quarter
Anika Therapeutics's current ratio has decreased by 28% YoY
Anika Therapeutics's debt is 83% lower than its equity
ANIK's equity is down by 7% year-on-year but it is up by 2.5% since the previous quarter
The debt to equity is up by 6% year-on-year but it is down by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.